BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) saw a downside of -1.07% to $6.95 after subtracting -$0.07 on Wednesday. The 5-day average trading volume is 3,749,580 shares of the company’s common stock. It has gained $7.87 in the past week and touched a new high 2 times within the past 5 days. An average of 3,004,915 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,702,016.
BCRX’s 1-month performance is -3.41% or -$0.02 on its low of $6.62 reached on 08/08/23. The company’s shares have touched a 52-week low of $6.62 and high of $15.12, with the stock’s rally to the 52-week high happening on 01/06/23. YTD, BCRX has lost -39.50% or -$4.52 and has reached a new high 3 times. However, the current price is down -54.07% from the 52-week high price.
Insider Transactions
BCRX stock investors last saw insider trading activity on Jun 15.SANDERS MACHELLE (Director) most recently sold 4,000 shares at $7.98 per share on Jun 15. This transaction cost the insider $31,920. Director, Hutson Nancy J, sold 12,866 shares at a price of $8.04 on Jun 14. Then, on Apr 03, Chief R&D Officer Thackray Helen M. sold 7,000 shares at a price of $8.29 per share. This transaction amounted to $58,030.
Valuation Metrics
BCRX stock has a beta of 1.88. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 3.99.
BioCryst Pharmaceuticals Inc.’s quick ratio for the period ended June 29 was 5.40, with the current ratio over the same period at 5.80. In terms of profitability, the gross margin trailing 12 months is 97.40%. The trailing 12-month EBITDA margin is -54.28% while for the period ending June 29, BioCryst Pharmaceuticals Inc.’s operating margin was -48.40%. The firm’s gross profit as reported stood at $264.42 million against revenue of $270.83 million.
Earnings Surprise
For the quarterly period ending June 29 this year, BioCryst Pharmaceuticals Inc.’s cash and short-term investments amounted to $264.46 million against total debt of $755.36 million. Net income and sales went up compared to those figures reported in the previous quarter. Net income grew 21.86% to -$75.33 million, while revenue of -$53.33 million was 29.2% off the previous quarter. Analysts expected BCRX to announce -$0.23 per share in earnings in its latest quarter, but it posted -$0.4, representing a -73.90% surprise. EBITDA for the quarter stood at more than -$23.13 million. BCRX stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 918.6 million, with total debt at $755.36 million. Shareholders hold equity totaling $189.49 million.
Let’s look briefly at BioCryst Pharmaceuticals Inc. (BCRX) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 08 August was 43.98% to suggest the stock is trending Neutral, with historical volatility in this time period at 85.92%.
The stock’s 5-day moving average is $7.07, reflecting a +0.14% or $0.01 change from its current price. BCRX is currently trading -3.06% above its 20-day SMA, -14.81% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 by -13.11% and SMA200 by-48.60%.
Stochastic %K and %D was 19.33% and 28.73% and the average true range (ATR) pointed at 0.44. The RSI (14) points at 44.58%, while the 14-day stochastic is at 25.56% with the period’s ATR at 0.40. The stock’s 9-day MACD Oscillator is pointing at -0.25 and -0.42 on the 14-day charts.
Analyst Ratings
In the most recent analyst report for BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Jefferies upgraded it to a Buy rating. They previously had a Hold rating on the stock. Analysts offering their rating for BCRX stock have a consensus rating for the stock as Overweight. Currently, 0 brokerage advisors rate BCRX as a “sell,”, while 3 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 8 have offered a “buy” rating.
